Skip to main content

Table 3 Observed changes from baseline values over the study period (mean ± standard error)

From: Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy

  

6 mo

12 mo

18 mo

24 mo

  

Mean ± SEM

P

Mean ± SEM

P

Mean ± SEM

P

Mean ± SEM

P

Cholesterol change

E

11.5 ± 5.6

0.046

14.4 ± 5

0.005

15.3 ± 7

0.037

8.9 ± 7.4

NS

 

O

16.8 ± 4.7

0.001

21.6 ± 4.1

<0.001

24 ± 5.3

<0.001

17 ± 6

0.009

HDL change

E

-4.3 ± 1.8

0.025

-3 ± 2.3

NS

-6.5 ± 2.6

0.024

-8.3 ± 2.1

0.001

 

O

2.2 ± 1.5

NS

1.7 ± 1.4

NS

1.5 ± 1.2

NS

1.1 ± 1.9

NS

LDL change

E

24.3 ± 6.3

0.001

20.1 ± 6.3

0.004

22.7 ± 9.5

0.030

32.1 ± 8.1

0.001

 

O

19.8 ± 5.7

0.002

22.3 ± 4.9

<0.001

30.4 ± 6.2

<0.001

23 ± 8.4

0.015

Total TRG change

E

-24.1 ± 7.8

0.004

-32.2 ± 7.6

<0.001

-26.8 ± 9.3

0.008

-20.7 ± 9.6

0.040

 

O

-13.7 ± 6.1

0.031

-17.6 ± 7.6

0.026

-9.4 ± 7.2

NS

-19.8 ± 9

0.038

  1. E = exemestane; O = observation.
  2. Note: t-test P values, NS = nonsignificant when P > 0.05.